No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
No one on the platform currently holds 2222.
No tracked institution reports a position in 2222 as of their last filing.
No one on the platform has traded 2222 yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Analyst estimates unavailable for this ticker.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$ICCC MSU is conducting the investigational studies for retain. We get the results of that test late September/october. MSU is known for this type of research. https://www.canr.msu.edu/news/anti-inflammatories-antimicrobial-resistance
View on StockTwits ↗
$ICCC retain data and plan due late september to october
View on StockTwits ↗
$ICCC https://finance.yahoo.com/healthcare/articles/immucell-announces-unaudited-financial-results-200500226.html
View on StockTwits ↗$ICCC https://marketwirenews.com/stock/iccc/news/immucell-announces-a-12-increase-in-product-sales-in-8316804107489173.html?utm_source=rss-twitter
View on StockTwits ↗
$ICCC retsin data at MSU must look good. Partnership for retain getting closer
View on StockTwits ↗
$ICCC CEO purchased 8,000 shares at $9.49 for a total of $75,960. te Boekhorst Paul Francis Olivier now owns 17,785 shares. https://ceo-buys.com
View on StockTwits ↗
$ICCC lets get a retain partner update tommorrow. Would love to hear "multiple parties interested"
View on StockTwits ↗
$ICCC https://www.tradingview.com/news/zacks:2094eeaa2094b:0-immucell-q1-earnings-rise-y-y-as-sales-climb-on-strong-demand/
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.